HC Wainwright Issues Positive Outlook for CNTX Earnings

Context Therapeutics Inc. (NASDAQ:CNTX) – HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Context Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.42) EPS, FY2029 earnings at ($0.23) EPS and FY2030 earnings at $0.00 EPS.

A number of other equities analysts also recently commented on the stock. Lifesci Capital downgraded shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Citigroup reiterated an “outperform” rating on shares of Context Therapeutics in a report on Thursday. Weiss Ratings cut Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. Maxim Group decreased their price target on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Finally, Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Context Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Trading Down 6.5%

Shares of CNTX opened at $0.45 on Monday. Context Therapeutics has a 12 month low of $0.43 and a 12 month high of $3.62. The firm has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.91. The stock has a market capitalization of $41.56 million, a price-to-earnings ratio of -0.94 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06).

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently made changes to their positions in the company. Virtu Financial LLC bought a new stake in Context Therapeutics in the 4th quarter valued at $43,000. Deutsche Bank AG bought a new position in Context Therapeutics during the 2nd quarter worth $50,000. Sanctuary Advisors LLC bought a new position in Context Therapeutics during the 1st quarter worth $51,000. Bank of New York Mellon Corp acquired a new stake in shares of Context Therapeutics during the second quarter worth $61,000. Finally, Quadrature Capital Ltd acquired a new stake in shares of Context Therapeutics during the fourth quarter worth $68,000. Institutional investors own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.